As of 3:59pm ET
| +2.58 / +5.48%|
The 9 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 60.00, with a high estimate of 82.00 and a low estimate of 54.00. The median estimate represents a +20.89% increase from the last price of 49.63.
The current consensus among 10 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.